# Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

> **NCT03699384** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Minimal Residual Disease

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03699384
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-10-03
- **Primary completion:** 2019-02-18
- **Final completion:** 2019-02-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study sponsor discontinued support
- **Last updated:** 2019-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03699384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03699384, "Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03699384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*